Sign in
AIXC Stock Price, Chart, Stats & News
AIxCrypto Holdings, Inc.
Save
7.53M
Market cap
–
Current P/E
–
Forward P/E
AIXC chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | -0.08% |
ROA | -16.62% |
ROE | -72.97% |
D/E | 0.08x |
Interest coverage ratio | -9.74x |
AIXC valuation
P/E | – |
P/S | – |
P/B | 0.02x |
P/CF | -0.10x |
P/FCF | -0.84x |
P/OCF | -0.10x |
PEG | -0.00x |
EV multiple | -6.40x |
About
AIxCrypto Holdings, Inc. is a clinical-stage biopharmaceutical company committed to discovering and developing innovative treatments for both adult and pediatric oncology. Its leading investigational therapeutic, QN-302, is a small molecule G-quadruplexes (G4)-selective transcription inhibitor currently progressing through Phase I clinical trials for pancreatic cancer and a range of other solid tumors. The firm is also advancing Pan-RAS, a preclinical-stage program targeting advanced solid tumors.
Similar securities
Based on sector and market capitalization
Report issue